{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:47:53Z","timestamp":1761871673164,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["MCL7001-18"],"award-info":[{"award-number":["MCL7001-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007273","name":"Weill Cornell Medical College","doi-asserted-by":"publisher","award":["1-UL1-TR002384-01"],"award-info":[{"award-number":["1-UL1-TR002384-01"]}],"id":[{"id":"10.13039\/100007273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clml.2021.07.035","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T11:52:51Z","timestamp":1627905171000},"page":"e57-e64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Ahmed","family":"Toure","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Christos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Cancer Stat Facts: Non-Hodgkin Lymphoma. Vol 2021","key":"10.1016\/j.clml.2021.07.035_bib0001"},{"year":"2019","author":"Society","series-title":"Treating B-Cell Non-Hodgkin Lymphoma","key":"10.1016\/j.clml.2021.07.035_bib0002"},{"year":"2012","author":"Katzung","series-title":"Basic and Clinical Pharmacology","key":"10.1016\/j.clml.2021.07.035_bib0003"},{"key":"10.1016\/j.clml.2021.07.035_bib0004","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/ncomms2921","article-title":"Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin","volume":"4","author":"Pang","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2021.07.035_bib0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.clml.2021.07.035_bib0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy.","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.clml.2021.07.035_bib0007","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.07.035_bib0008","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.035_bib0009","first-page":"196","article-title":"Doxorubicin cardiotoxicity in African Americans","volume":"96","author":"Hasan","year":"2004","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.clml.2021.07.035_bib0010","doi-asserted-by":"crossref","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2021.07.035_bib0011","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/10428194.2012.708751","article-title":"Examining racial differences in diffuse large B-cell lymphoma presentation and survival","volume":"54","author":"Flowers","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.07.035_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","article-title":"Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients","volume":"13","author":"Nayak","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clml.2021.07.035_bib0013","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.168.19.2138","article-title":"Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis","volume":"168","author":"Bahrami","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clml.2021.07.035_bib0014","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.amjcard.2016.02.017","article-title":"Impact of race, ethnicity, and multimodality biomarkers on the incidence of new-onset heart failure with preserved ejection fraction (from the multi-ethnic study of atherosclerosis)","volume":"117","author":"Silverman","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clml.2021.07.035_bib0015","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jacc.2013.01.022","article-title":"Lifetime risk for heart failure among white and black Americans: cardiovascular lifetime risk pooling project","volume":"61","author":"Huffman","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clml.2021.07.035_bib0016","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2021.07.035_bib0017","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American heart association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2021.07.035_bib0018","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.07.035_bib0019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clml.2021.07.035_bib0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/clc.4960210911","article-title":"Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography","volume":"21","author":"Cottin","year":"1998","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clml.2021.07.035_bib0021","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:20Z","timestamp":1761871040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2152265021003189"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.035","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}